185 related articles for article (PubMed ID: 8165623)
41. Characterising the Subsite Specificity of Urokinase-Type Plasminogen Activator and Tissue-Type Plasminogen Activator using a Sequence-Defined Peptide Aldehyde Library.
Li CY; de Veer SJ; Law RHP; Whisstock JC; Craik DJ; Swedberg JE
Chembiochem; 2019 Jan; 20(1):46-50. PubMed ID: 30225958
[TBL] [Abstract][Full Text] [Related]
42. Urokinase-type plasminogen activator in human aqueous humor.
Bernatchez SF; Tabatabay C; Belin D
Invest Ophthalmol Vis Sci; 1992 Aug; 33(9):2687-92. PubMed ID: 1639615
[TBL] [Abstract][Full Text] [Related]
43. Measuring plasminogen activator inhibitor activity in plasma by two enzymatic assays.
Chiu WC; Gann DS; Darlington DN
J Biochem Biophys Methods; 2000 Sep; 45(2):127-40. PubMed ID: 10989129
[TBL] [Abstract][Full Text] [Related]
44. Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells.
Karlan BY; Rivero JA; Crabtree ME; Littlefield BA
Mol Endocrinol; 1989 Jun; 3(6):1006-13. PubMed ID: 2500590
[TBL] [Abstract][Full Text] [Related]
45. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma.
Huisman LG; van Griensven JM; Kluft C
Thromb Haemost; 1995 Mar; 73(3):466-71. PubMed ID: 7667830
[TBL] [Abstract][Full Text] [Related]
46. Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein.
Shireman PK; McCarthy WJ; Pearce WH; Shively VP; Cipollone M; Kwaan HC; Yao JS
J Vasc Surg; 1996 Nov; 24(5):719-24. PubMed ID: 8918314
[TBL] [Abstract][Full Text] [Related]
47. Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system.
Laurell M; Christensson A; Abrahamsson PA; Stenflo J; Lilja H
J Clin Invest; 1992 Apr; 89(4):1094-101. PubMed ID: 1372913
[TBL] [Abstract][Full Text] [Related]
48. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J
EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560
[TBL] [Abstract][Full Text] [Related]
49. Preliminary studies on the role of plasminogen activator in seminal plasma of human and rhesus monkey.
Liu K; Liu YX; Du Q; Zhou HM; Lin X; Hu ZY; Zhang GY; Zhang GH
Mol Hum Reprod; 1996 Feb; 2(2):99-104. PubMed ID: 9238665
[TBL] [Abstract][Full Text] [Related]
50. The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine.
Chandler WL; Levy WC; Stratton JR
Circulation; 1995 Nov; 92(10):2984-94. PubMed ID: 7586269
[TBL] [Abstract][Full Text] [Related]
51. Production of plasminogen activators (PAs) in bovine cumulus-oocyte complexes during maturation in vitro: effects of epidermal growth factor on production of PAs in oocytes and cumulus cells.
Park KW; Choi SH; Song XX; Funahashi H; Niwa K
Biol Reprod; 1999 Jul; 61(1):298-304. PubMed ID: 10377062
[TBL] [Abstract][Full Text] [Related]
52. The imbalance of plasminogen activators and inhibitor in preeclampsia.
Gao M; Nakabayashi M; Sakura M; Takeda Y
J Obstet Gynaecol Res; 1996 Feb; 22(1):9-16. PubMed ID: 8624901
[TBL] [Abstract][Full Text] [Related]
53. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
[TBL] [Abstract][Full Text] [Related]
54. Purification and characterization of tissue-type plasminogen activator in maxillary mucosa with chronic inflammation.
Hamaguchi Y; Ohi M; Sakakura Y; Miyoshi Y
Thromb Haemost; 1985 Aug; 54(2):485-9. PubMed ID: 3936218
[TBL] [Abstract][Full Text] [Related]
55. Characterization of urokinase-type plasminogen activator of rat decidual tissue.
Pawse AR; Tarachand U
Biochem Mol Biol Int; 1994 Jul; 33(4):775-84. PubMed ID: 7981665
[TBL] [Abstract][Full Text] [Related]
56. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
57. Tissue-type plasminogen activator level is decreased in human seminal plasma with abnormal liquefaction.
Arnaud A; Schved JF; Gris JC; Costa P; Navratil H; Humeau C
Fertil Steril; 1994 Apr; 61(4):741-5. PubMed ID: 8150119
[TBL] [Abstract][Full Text] [Related]
58. Components of the plasminogen activation system promote engraftment of porous polyethylene biomaterial via common and distinct effects.
Reichel CA; Hessenauer ME; Pflieger K; Rehberg M; Kanse SM; Zahler S; Krombach F; Berghaus A; Strieth S
PLoS One; 2015; 10(2):e0116883. PubMed ID: 25658820
[TBL] [Abstract][Full Text] [Related]
59. Downregulation of urokinase-type and tissue-type plasminogen activators in a rabbit model of renal ischemia/reperfusion.
Sugiki M; Omura S; Yoshida E; Itoh H; Kataoka H; Maruyama M
J Biochem; 2002 Sep; 132(3):501-8. PubMed ID: 12204121
[TBL] [Abstract][Full Text] [Related]
60. Intracellular localization of protein C inhibitor (PCI) and urinary plasminogen activator in renal tubular epithelial cells from humans and human PCI gene transgenic mice.
Song Z; Ma N; Hayashi T; Gabazza EC; Sugimura Y; Suzuki K
Histochem Cell Biol; 2007 Oct; 128(4):293-300. PubMed ID: 18193533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
